Genprex Inc
Change company Symbol lookup
Select an option...
GNPX Genprex Inc
BAC Bank of America Corp
RYB RYB Education Inc
RETA Reata Pharmaceuticals Inc
RDFN Redfin Corp
RCUS Arcus Biosciences Inc
RBWNY Koninklijke Boskalis Westminster NV
RBII Rising Biosciences Inc
RAD Rite Aid Corp
QDEL Quidel Corp
Go

Health Care : Biotechnology |
Company profile

Genprex, Inc. is a clinical stage gene therapy company. The Company is focused on developing cancer-based upon its novel proprietary technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. The Company’s Oncoprex is lead product candidate, is the subject of an ongoing Phase I/II clinical trials at The University of Texas MD Anderson Cancer Center in patients with late stage non-small cell lung cancer, or NSCLC. Oncoprex gene therapy platform may also be effective with respect to other types of cancer, including breast, head and neck, renal cell (kidney), soft tissue cancer. The Company’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles. The Company’s Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis.

Closing Price
$2.84
Day's Change
0.07 (2.53%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.85
Day's Low
2.66
Volume
(Average)
Volume:
1,000,310

10-day average volume:
1,083,425
1,000,310

Company Profile

Genprex, Inc. is a clinical stage gene therapy company. The Company is focused on developing cancer-based upon its novel proprietary technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. The Company’s Oncoprex is lead product candidate, is the subject of an ongoing Phase I/II clinical trials at The University of Texas MD Anderson Cancer Center in patients with late stage non-small cell lung cancer, or NSCLC. Oncoprex gene therapy platform may also be effective with respect to other types of cancer, including breast, head and neck, renal cell (kidney), soft tissue cancer. The Company’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles. The Company’s Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
3.90x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

May 2020
Current Month
4.0M
Previous Month
3.6M
Percent of Float
15.93%
Days to Cover
0.5828 Days

Share Information

GNPX is in a share class of common stock
Float
25.3M
Shares Outstanding
32.9M
Institutions Holding Shares
23
8.06%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • J. Rodney VarnerChmn.
  • Ryan M. ConferCFO
  • Michael Thomas RedmanCOO
  • Catherine M. VaczyExec.VP
  • Brent LongneckerDir.

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.